Sugi Predict

Sugi Predict / Compounds / SCHEMBL5250993

SCHEMBL5250993

SCHEMBL5250993

COc1cccc(OC)c1Cc1c(OC)cccc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.55
▸ CA1 P00915 4/20 0.55
▸ CA7 P43166 3/20 0.55
▸ CA9 Q16790 3/20 0.55
▸ CA12 O43570 2/20 0.55
▸ CA14 Q9ULX7 2/20 0.55
▸ CA4 P22748 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ TP53 P04637 2/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ NQO1 P15559 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23499986 0.84 CA1 (0.44) CA2CA1CA7CA9CA12
SCHEMBL2090430 0.84 IDO1 (0.53) CA2CA1CA7CA9CA12
SCHEMBL28281191 0.84 ALDH1A1 (0.58) CA2CA1CA7CA9CA12
SCHEMBL3728677 0.84 LTA4H (0.52) CA2CA1CA7CA9CA12
SCHEMBL1547302 0.81 CA1 (0.52) CA2CA1CA7CA9CA12
SCHEMBL2549434 0.80 HTR7 (0.50) CA2CA1CA7CA9CA12
SCHEMBL9046597 0.80 ALDH1A1 (0.56) CA2CA1CA7CA9CA12
SCHEMBL9045401 0.80 ALDH1A1 (0.42) CA2CA1CA7CA9CA12
SCHEMBL4814597 0.80 TUBB1 (0.42) CA2CA1CA7CA9CA12
SCHEMBL774889 0.79 CA1 (0.50) CA2CA1CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400520-A1 CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER The University of Tokyo (JP) 2024-07-17 — — EP disclosed
WO-2023037849-A1 CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER 国立大学法人 東京大学 2023-03-16 — — WO disclosed
US-20210061980-A1 MULTI-COMPONENT, POLAR GROUP-CONTAINING OLEFIN COPOLYMER JAPAN POLYETHYLENE CORPORATION (JP) 2021-03-04 — — US disclosed
EP-1361225-B1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS SANKYO CO (JP) 2007-11-07 — — EP disclosed
US-7122666-B2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-10-17 — — US disclosed
US-7091352-B2 Compounds substituted with bicyclic amino groups SANKYO COMPANY, LIMITED (JP) 2006-08-15 — — US disclosed
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-06-15 — — US disclosed
EP-1377577-B1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO CO (JP) 2006-06-14 — — EP disclosed
US-20050283006-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2005-12-22 — — US disclosed
US-20040147525-A1 Compounds substituted with bicyclic amino groups SANKYO COMPANY, LIMITED (JP) 2004-07-29 — — US disclosed
EP-1070711-B1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 2004-04-14 — — EP disclosed
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2004-03-18 — — US disclosed
EP-1377577-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES Sankyo Company Limited (JP) 2004-01-07 — — EP disclosed
US-6670512-B2 Molecular templates for metal complexation STRYKER JEFFREY MARK (CA) 2003-12-30 — — US disclosed
EP-1361225-A1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS Sankyo Company, Limited (JP) 2003-11-12 — — EP disclosed
EP-1352906-A1 COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY Sankyo Company, Limited (JP) 2003-10-15 — — EP disclosed
US-20020183540-A1 Substituted tetraarylethylene compounds THE GOVERNORS OF THE UNIVERSITY OF ALBERTA 2002-12-05 — — US disclosed
EP-1243589-A1 Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses Sankyo Company Limited (JP) 2002-09-25 — — EP disclosed
WO-2002057264-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO COMPANY LIMITED (JP) 2002-07-25 — — WO disclosed
EP-1070711-A2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183540-A1 Substituted tetraarylethylene compounds ABL1, ETV6, ALK CA2 4493/4885CA1 4491/4885CA7 3094/4885
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1A, IL1B CA2 3488/4885CA1 4413/4885CA7 3624/4885
US-20050283006-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, CNKSR1, IL1A CA2 3213/4885CA1 4288/4885CA7 3113/4885
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1B, IL1A CA2 3628/4885CA1 4541/4885CA7 3367/4885
US-20040147525-A1 Compounds substituted with bicyclic amino groups IL2, IL1B, IL4I1 CA2 1838/4885CA1 2150/4885CA7 2303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.